Abstract
Chemotherapy is a cornerstone of cancer treatment, but it can also induce immune suppression, which can have significant implications for patient outcomes. This review paper aims to give a general overview of how chemotherapy affects the immune system and how it affects cancer treatment. Chemotherapy can directly affect immune cells, leading to cytotoxic effects, cell differentiation and function alterations, and cell communication and signaling pathways disruptions. Such immune suppression can weaken the anti-tumor immune response and increase the risk of immune-related toxicities. Understanding the mechanisms of chemotherapy-induced immune suppression is crucial for optimizing treatment strategies. Strategies to mitigate immune suppression include immunomodulatory agents as adjuvants to chemotherapy, combination therapies to enhance immune function, and supportive care measures of the immune system. Additionally, identifying potential biomarkers to predict immune suppression and guide treatment decisions holds promise for personalized cancer medicine. Future directions in this field involve further elucidating underlying mechanisms, exploring novel combination therapies, and developing targeted interventions to minimize immune suppression. By understanding and addressing chemotherapy-induced immune suppression, we can optimize cancer treatment strategies, enhance the anti-tumor immune response, and improve patient outcomes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
This document includes citations for all the data that were analyzed throughout the literature review.
REFERENCES
Abu-Eid R, Samara RN, Ozbun L, Abdalla MY, Berzofsky JA, Friedman KM, Mkrtichyan M (2017) Selective inhibition of regulatory T-cells by targeting the PI3K-Akt pathway. Cancer Immunology Research 5(7):563–575. https://doi.org/10.1158/2326-6066.CIR-16-0337
American Cancer Society. (2021). Chemotherapy. Retrieved from https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy.html
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine 372(4):311–319. https://doi.org/10.1056/NEJMoa1411087
Bai R, Lv Z, Xu D, Cui J (2020) Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 8:1–17. https://doi.org/10.1186/s40364-020-00209-0
Beghdadi W, Madjene LC, Benhamou M, Charles N, Gautier G, Launay P, Blank U (2011) MasT-cells as cellular sensors in inflammation and immunity. Frontiers in immunology 2:37. https://doi.org/10.3389/fimmu.2011.00037
Bende RJ, Aarts WM, van Noesel CJ (2011) Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. Leukemia 25(3):387–398. https://doi.org/10.1038/leu.2010.288
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine 24(5):541–550. https://doi.org/10.1038/s41591-018-0014-x
Bolivar-Wagers S, Larson JH, Jin S, Blazar BR (2022) Cytolytic CD4+ and CD8+ regulatory T-cells and implications for developing immunotherapies to combat graft-versus-host disease. Front Immunol 13:1–21. https://doi.org/10.3389/fimmu.2022.864748
Cao Y, Wang X, Jin T, Tian Y, Dai C, Widarma C et al (2020) Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal transduction and targeted therapy 5(1):250. https://doi.org/10.1038/s41392-020-00318-w
Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 91(12):2214–2221. https://doi.org/10.1002/1097-0142(20010615)91:12<2214::aid-cncr1274>3.0.co;2-p
Casadevall A, Dadachova E (2004) Antibody-mediated chemotherapy: recent advances and future prospects. Trends in Biotechnology 22(9):424–430. https://doi.org/10.1016/j.tibtech.2004.06.010
Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. The Journal of Experimental Medicine 202(12):1691–1701. https://doi.org/10.1084/jem.20050915
Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S et al (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142(5):699–713. https://doi.org/10.1016/j.cell.2010.07.044
Choudhury N, Nakka KK, Choudhury SR, Konar S (2018) Immune system modulation and role of cytokines as immunotherapy in cancer treatment. International Journal of Cell Biology 2018:5167342. https://doi.org/10.1155/2018/5167342
Constantino J, Gomes C, Falcão A, Neves BM, Cruz MT (2017) Dendritic cell-based immunotherapy: a basic review and recent advances. Immunologic research 65:798–810. https://doi.org/10.1007/s12026-017-8957-6
Coventry BJ (2019) Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy. Therapeutic Advances in Vaccines and Immunotherapy.:7. https://doi.org/10.1177/2515135519862234
Crotty S (2019) T follicular helper cell biology: a decade of discovery and diseases. Immunity 50(5):1132–1148. https://doi.org/10.1016/j.immuni.2019.04.011
De Milito A, Younes A (2008) The central role of lymphocytes in the cancer microenvironment. Oncology 72(3-4):124–132. https://doi.org/10.1159/000151563
Del Prete A, Salvi V, Soriani A et al (2023) Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol 20:432–447. https://doi.org/10.1038/s41423-023-00990-6
Deptuła M, Zieliński J, Wardowska A, Pikuła M (2019) Wound healing complications in oncological patients: perspectives for cellular therapy. Advances in Dermatology and Allergology/PostępyDermatologiiiAlergologii 36(2):139–146. https://doi.org/10.5114/ada.2019.84517
Emens LA (2018) Breast cancer immunotherapy: Facts and hopes. Clinical Cancer Research 24(3):511–520. https://doi.org/10.1158/1078-0432.CCR-16-3001
Facciabene A, Motz GT (2012) Tumor-infiltrating lymphocytes: A critical review of the literature. Journal of Immunotherapy 35(7):585–598. https://doi.org/10.1097/CJI.0b013e318275eebf
Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: Impact on clinical outcome. Nature Reviews Cancer 12(4):298–306. https://doi.org/10.1038/nrc3245
Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H (2006) Immune resistance orchestrated by the tumor microenvironment. Immunological Reviews 213(1):131–145. https://doi.org/10.1111/j.1600-065X.2006.00442.x
Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology 14(10):1014–1022. https://doi.org/10.1038/ni.2703
Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G (2015) Immunogenic cell death in cancer and infectious disease. Nature Reviews Immunology 17(2):97–111. https://doi.org/10.1038/nri.2016.107
Galluzzi L, Senovilla L, Zitvogel L, Kroemer G (2012) The secret ally: immunostimulation by anticancer drugs. Nature Reviews. Drug Discovery 11(3):215–233. https://doi.org/10.1038/nrd3626
Gao L, Zhang L, Hu J, Li F, Shang Z (2020a) Immune checkpoint inhibitors combination therapy for lymphoma: current knowledge and future directions. Frontiers in Immunology 11:1679. https://doi.org/10.3389/fimmu.2020.01679
Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Smyth MJ (2020b) Endogenous tumor-reactive CD8+ T-cells in cancer immunotherapy: Potentials and challenges. Frontiers in Immunology 11:1–18. https://doi.org/10.3389/fimmu.2020.00786
Garg AD, Agostinis P (2017) Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunological Reviews 280(1):126–148. https://doi.org/10.1111/imr.12574
Gennery AR, Lankester A, Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2019) Long term outcome and immune function after hematopoietic stem cell transplantation for primary immunodeficiency. Front Pediatr 24(7):1–7. https://doi.org/10.3389/fped.2019.00381
Gonzalez H, Hagerling C, Werb Z (2018) Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 32(19–20):1267–1284. https://doi.org/10.1101/gad.314617.118
Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133–150. https://doi.org/10.1038/s41568-019-0116-x
Hurez V, Padron ÁS, Svatek RS, Curiel TJ, Kim J (2015) Immune-based therapy in metastatic renal cell carcinoma: current and future perspectives. Immunotherapy 7(2):191–202. https://doi.org/10.2217/imt.14.102
Janssens S, Beyaert R (2003) Role of Toll-like receptors in pathogen recognition. Clinical microbiology reviews 16(4):637–646. https://doi.org/10.1128/CMR.16.4.637-646.2003
Joseph GS, Joseph CH (2006) Evidence accumulating in support of cancer vaccines combined with chemotherapy: A pragmatic review of past and present efforts. International Journal of Oncology 29(4):765–777. https://doi.org/10.3892/ijo.29.4.765
Joshi SS, Badgwell BD (2021) Current treatment and recent progress in gastric cancer. CA: A Cancer Journal for Clinicians 71(3):264–279. https://doi.org/10.3322/caac.21627
Jungles KM, Holcomb EA, Pearson AN, Jungles KR, Bushop CR, Pierce LJ, Green MD, Speers CW (2022) Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Front. Oncol. 12. https://doi.org/10.3389/fonc.2022.1022542
Katz J, Feldman MA, Bass EB, Lubomski LH, Tielsch JM, Petty BG et al (2001) Adverse intraoperative medical events and their association with anesthesia management strategies in cataract surgery. Ophthalmology 108(10):1721–1726. https://doi.org/10.1016/S0161-6420(01)00696-7
Khalil DN, Smith EL, Brentjens RJ, Wolchok JD (2016) The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13(5):273–290. https://doi.org/10.1038/nrclinonc.2016.25
Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US et al (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113(2):293–301. https://doi.org/10.1002/cncr.23552
Koh AY, Priebe GP, Ray C, Van Rooijen N, Pier GB (2009) Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infection and immunity 77(12):5300–5310. https://doi.org/10.1128/IAI.00781-09
Kroschinsky F, Stölzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M et al (2017) New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Critical Care 21:1–11. https://doi.org/10.1186/s13054-016-1588-4
Lana S, U'ren L, Plaza S, Elmslie R, Gustafson D, Morley P, Dow S (2007) Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Journal of Veterinary Internal Medicine 21(4):764–769. https://doi.org/10.1111/j.1939-1676.2007.tb03096.x
Lee L, Gupta M, Sahasranaman S (2016) Immune checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. The Journal of Clinical Pharmacology 56(2):157–169. https://doi.org/10.1002/jcph.596
Lee YT, Tan YJ, Oon CE (2018) Molecular targeted therapy: Treating cancer with specificity. European Journal of Pharmacology 834:188–196. https://doi.org/10.1016/j.ejphar.2018.07.010
Lenz G, Wright GW, Dave SS (2015) The role of the tumor microenvironment in chemotherapy-resistant lymphoma. Cancer Microenvironment 8(2):59–73. https://doi.org/10.1007/s12307-014-0159-3
Levi M, Salaroli R, Parenti F, Maria R D, Zannoni A, Bernardini C, Gola C, Brocco A, Marangio A, Benazzi C, Muscatello L V, Brunetti B, Forni M, Sarli G, National institute of health 2018 https://doi.org/10.1186/s12917-020-02709-5
Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H et al (2013) Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38(4):729–741. https://doi.org/10.1016/j.immuni.2013.03.003
Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME et al (1995) Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84(7):2221–2228. https://doi.org/10.1182/blood.v84.7.2221.bloodjournal8472221
Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT (2015) Complement system part II: role in immunity. Frontiers in immunology 6:257. https://doi.org/10.3389/fimmu.2015.00257
Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2017) Combination therapy in combating cancer. Oncotarget 8(23):38022–38043. https://doi.org/10.18632/oncotarget.16723
Nimmerjahn F, Ravetch JV (2008) Fcγ receptors: old friends and new family members. Immunity 28(1):18–28. https://doi.org/10.1016/j.immuni.2007.11.020
O’Donnell JS, Teng MWL, Smyth MJ (2019) Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 16:151–167. https://doi.org/10.1038/s41571-018-0142-8
Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L (2016) Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy. Annals of Oncology 27(8):1482–1492. https://doi.org/10.1093/annonc/mdw168
Pone EJ, Zan H (2012) Antibody isotype diversification and the regulation of antibody responses. The Journal of Immunology 189(12):5173–5174. https://doi.org/10.4049/jimmunol.1290061
Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology 33(17):1974–1982. https://doi.org/10.1200/JCO.2014.59.4358
Poulain S, Roumier C, Venet F, Lepape A, Meilleroux J (2019) Plasma cells: from production to pathologic disorders. European Journal of Internal Medicine 62:10–16. https://doi.org/10.1016/j.ejim.2018.09.015
Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A, Fride E et al (1994) Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides. Cancer Research 54(4):1049–1057
Ramakrishnan R, Huang C, Cho HI (2020) Immunomodulatory effects of conventional chemotherapy and targeted therapy on the tumor microenvironment. Advances in Experimental Medicine and Biology 1248:83–96. https://doi.org/10.1007/978-3-030-38397-7_4
Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK et al (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. The Journal of Experimental Medicine 203(5):1259–1271. https://doi.org/10.1084/jem.20052494
Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: Harnessing the T-cell response. Nature Reviews Immunology 12(4):269–281. https://doi.org/10.1038/nri3191
Ruffell B, Coussens LM (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27(4):462–472. https://doi.org/10.1016/j.ccell.2015.02.015
Schatton T, Schütte U, Frank NY, Zhan Q, Hoerning A, Robles SC, Zhou J, Hodi FS, Spagnoli GC, Murphy GF, Frank MH (2010) Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 70(2):697–708. https://doi.org/10.1158/0008-5472.CAN-09-1592
Schirrmacher V (2019) From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). International Journal of Oncology 54:407–419. https://doi.org/10.3892/ijo.2018.4661
Seo H, Jeong HW (2020) Chemotherapy-induced immunosuppression and tumor immune evasion. Immune Network 20(1):e9. https://doi.org/10.4110/in.2020.20.e9
Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nature Reviews Cancer 8(11):887–899. https://doi.org/10.1038/nrc2501
Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: an eternal fight between good and evil. The Journal of Clinical Investigation 125(9):3347–3355. https://doi.org/10.1172/JCI80007
Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F et al (2018) Macrophage plasticity, polarization, and function in health and disease. Journal of cellular physiology 233(9):6425–6440. https://doi.org/10.1002/jcp.26429
Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161(2):205–214. https://doi.org/10.1016/j.cell.2015.03.030
Shin DS, Ribas A (2015) The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Current Opinion in Immunology 33:23–35. https://doi.org/10.1016/j.coi.2015.01.006
Silk AW, Barker CA, Bhatia S, Bollin KB, Chandra S, Eroglu Z, Gastman BR, Kendra KL, Kluger H, Lipson E.J. Madden, K, (2022) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. J Immunother Cancer 10(7):1–27. https://doi.org/10.1136/jitc-2021-004434
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J et al (2014) Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine 20(11):1301–1309. https://doi.org/10.1038/nm.3708
Spranger S, Gajewski TF (2018) Impact of oncogenic pathways on evasion of antitumor immune responses. Cancer Discovery 8(8):1069–1087. https://doi.org/10.1158/2159-8290.CD-18-0266
Sun L, Yang X, Yuan Z, Wang H (2020) Metabolic reprogramming in immune response and tissue inflammation. Arterioscler Thromb Vascul Biol 40(9):1990–2001. https://doi.org/10.1161/ATVBAHA.120.314037
Teoh F, Pavelka N (2016) How chemotherapy increases the risk of systemic candidiasis in cancer patients: current paradigm and future directions. Pathogens 5(1):6. https://doi.org/10.3390/pathogens5010006
Topalian SL, Drake CG, Pardoll DM (2015) Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current Opinion in Immunology 27:1–7. https://doi.org/10.1016/j.coi.2014.11.001
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine 366(26):2443–2454. https://doi.org/10.1056/NEJMoa1200690
Tu L, Guan R, Yang H, Zhou Y, Hong W, Ma L, Zhao G, Yu M (2020) Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. Int J Cancer 147(2):423–39. https://doi.org/10.1002/ijc.32785
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571. https://doi.org/10.1038/nature13954
Ujjani C, Wang H, Skarbnik A, Jha R (2020) Clinical updates in managing and monitoring adverse events from CAR T-cells. Current Hematologic Malignancy Reports 15(3):193–203. https://doi.org/10.1007/s11899-020-00579-y
Vincent J, Mignot G (2018) Immunotherapy: New Weapons for Cancer Treatment. Medecine Sciences 34(1):47–54. https://doi.org/10.1051/medsci/20183401010
Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, Li X, Xiong W, Li G, Zeng Z, Guo C (2017) Role of tumor microenvironment in tumorigenesis. J Cancer 8(5):761–773. https://doi.org/10.7150/jca.17648
Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery 8(9):1069–1086. https://doi.org/10.1158/2159-8290.CD-18-0367
Weiskopf K, Weissman IL (2021) Macrophages are critical effectors of antibody therapies for cancer. MAbs 13(1):1900202. https://doi.org/10.1080/19420862.2020.1900202
Wu B, Shi X, Jiang M, Liu H (2023) Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Mol Cancer 22(1):1–22. https://doi.org/10.1186/s12943-023-01748-4
Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G (2008) The anticancer immune response: indispensable for therapeutic success? Journal of Clinical Investigation 118(6):1991–2001
Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine 8(328):328rv4. https://doi.org/10.1126/scitranslmed.aad7118
Funding
This manuscript did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
Conceptualization, methodology, validation, writing—review, SJ., A.K and AS.; formal analysis, resources, AS, SJ., and A.K.; data curation, AS, and SJ. All authors have read and agreed to the published version of the manuscript. The authors confirm that no paper mill and artificial intelligence was used.
Corresponding author
Ethics declarations
Ethical approval and Clinical trials
Not applicable
Consent to participate
Not applicable
Consent for publication
All authors have their consent to publish.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Sharma, A., Jasrotia, S. & Kumar, A. Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes. Naunyn-Schmiedeberg's Arch Pharmacol (2023). https://doi.org/10.1007/s00210-023-02781-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00210-023-02781-2